

19 February 2024

Intra-vitreous treatments for eye conditions

1. For the 4 months from September to December 2023, how many patients received the following intra-vitreous treatments for any eye condition:

Aflibercept	4875
Bevacizumab	10
Brolucizumab	0
Dexamethasone	64
Faricimab	241
Ranibizumab – Lucentis	904
Ranibizumab – Ongavia	0

2. For the patients above, how many were new to intra-vitreous treatment? Please provide the patient numbers by the treatments listed below, excluding patients who previously had received any of these treatments.

Aflibercept	96
Bevacizumab	6
Brolucizumab	0
Dexamethasone	22
Faricimab	34
Ranibizumab – Lucentis	13
Ranibizumab – Ongavia	0